nach oben

Seminars in Immunopathology

Erschienen in:

01.03.2013 | Review

Resolution of inflammation as a novel chemopreventive strategy

verfasst von: Ha-Na Lee, Hye-Kyung Na, Young-Joon Surh

Erschienen in: Seminars in Immunopathology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Acute inflammation, a physiologic response to protect cells from microbial infection and other noxious stimuli, is automatically terminated by endogenous anti-inflammatory and pro-resolving mediators to restore homeostatic conditions. However, if timely resolution of inflammation is failed, inflammation persists and can progress to a chronic inflammation which has long been thought as a predisposing factor to carcinogenesis. Excessive and pathologic inflammation causes DNA damage, genomic instability, epigenetic dysregulation, and alteration of intracellular signaling, all of which are involved in neoplastic transformation. To prevent chronic inflammation and resulting inflammation-promoted cancer development, understanding the process that resolves inflammation is essential. Resolution of inflammation is an active coordinated process regulated by distinct anti-inflammatory and pro-resolving endogenous lipid mediators, such as resolvins and lipoxins. The role of pro-inflammatory signaling in carcinogenesis has become more and more evident and well characterized, but the potential role of pro-resolving mediators in cancer prevention remains still elusive. In searching for an efficacious way to prevent chronic inflammation-associated cancer, the pro-resolving signal transduction pathways and their regulators should be unraveled.

Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428–435PubMedCrossRef

Philip M, Rowley DA, Schreiber H (2004) Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433–439PubMedCrossRef

Vendramini-Costa DB, Carvalho JE (2012) Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18:3831–3852PubMedCrossRef

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRef

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRef

Radisky DC, Kenny PA, Bissell MJ (2007) Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem 101:830–839PubMedCrossRef

Colville-Nash PR, Gilroy DW (2001) Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation. BioDrugs 15:1–9PubMedCrossRef

Stevens DL (1995) Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial-infections to toxic shock syndrome. Clin Infect Dis 21:977–980PubMedCrossRef

Rodriguez-Vita J, Lawrence T (2010) The resolution of inflammation and cancer. Cytokine Growth Factor Rev 21:61–65PubMedCrossRef

10.

Wilting J, Becker J, Buttler K, Weich HA (2009) Lymphatics and inflammation. Curr Med Chem 16:4581–4592PubMedCrossRef

11.

Huynh MLN, Fadok VA, Henson PM (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta 1 secretion and the resolution of inflammation. J Clin Invest 109:41–50PubMed

12.

Opal SM, DePalo VA (2000) Anti-inflammatory cytokines. Chest 117:1162–1172PubMedCrossRef

13.

Samuelsson B (1983) From studies of biochemical-mechanism to novel biological mediators—prostaglandin endoperoxides, thromboxanes, and leukotrienes. Angew Chem Int Edit 22:805–815CrossRef

14.

Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc 31:986–1000CrossRef

15.

Oshima H, Hioki K, Popivanova BK, Oguma K, Van Rooijen N, Ishikawa TO, Oshima M (2011) Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology 140:596–607.e7PubMedCrossRef

16.

Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A 100:9044–9049PubMedCrossRef

17.

McCoy JM, Wicks JR, Audoly LP (2002) The role of prostaglandin E₂ receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 110:651–658PubMed

18.

Byrum RS, Goulet JL, Snouwaert JN, Griffiths RJ, Koller BH (1999) Determination of the contribution of cysteinyl leukotrienes and leukotriene B₄ in acute inflammatory responses using 5-lipoxygenase- and leukotriene A₄ hydrolase-deficient mice. J Immunol 163:6810–6819PubMed

19.

Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191–1197PubMedCrossRef

20.

Lawrence T, Willoughby DA, Gilroy DW (2002) Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2:787–795PubMedCrossRef

21.

Il Lee S, Zuo XS, Shureiqi I (2011) 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in? Cancer Metastasis Rev 30:481–491PubMedCrossRef

22.

Serhan CN, Petasis NA (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111:5922–5943PubMedCrossRef

23.

Schwab JM, Chiang N, Arita M, Serhan CN (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447:869–874PubMedCrossRef

24.

Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, Serhan CN (2005) Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 102:7671–7676PubMedCrossRef

25.

Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N, Petasis NA, Levy BD, Serhan CN, Van Dyke TE (2006) RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J 20:401–403PubMed

26.

Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2:612–619PubMedCrossRef

27.

Spite M, Serhan CN (2010) Novel lipid mediators promote resolution of acute inflammation impact of aspirin and statins. Circ Res 107:1170–1184PubMedCrossRef

28.

Hammad H, de Heer HJ, Soullie T, Hoogsteden HC, Trottein F, Lambrecht BN (2003) Prostaglandin D₂ inhibits airway dendritic cell migration and function in steady state conditions by selective activation of the D prostanoid receptor 1. J Immunol 171:3936–3940PubMed

29.

Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M, Uchida K (2002) 15-Deoxy-Δ^12,14-prostaglandin J₂—a prostaglandin D₂ metabolite generated during inflammatory processes. J Biol Chem 277:10459–10466PubMedCrossRef

30.

Surh YJ, Na HK, Park JM, Lee HN, Kim W, Yoon IS, Kim DD (2011) 15-Deoxy-Δ^12,14-prostaglandin J₂, an electrophilic lipid mediator of anti-inflammatory and pro-resolving signaling. Biochem Pharmacol 82:1335–1351PubMedCrossRef

31.

Lee YC (2004) The role of PTEN in allergic inflammation. Arch Immunol Ther Exp 52:250–254

32.

Croker BA, Kiu H, Pellegrini M, Toe J, Preston S, Metcalf D, O’Donnell JA, Cengia LH, McArthur K, Nicola NA, Alexander WS, Roberts AW (2012) IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunol Cell Biol 90:124–129PubMedCrossRef

33.

Lawrence T, Bebien M, Liu GY, Nizet V, Karin M (2005) IKK alpha limits macrophage NF-kappa B activation and contributes to the resolution of inflammation. Nature 434:1138–1143PubMedCrossRef

34.

Balode L, Strazda G, Jurka N, Kopeika U, Kislina A, Bukovskis M, Beinare M, Gardjusina V, Taivans I (2012) Lipoxygenase-derived arachidonic acid metabolites in chronic obstructive pulmonary disease. Medicina (Kaunas) 48:292–298

35.

Wu WKK, Sung JJY, Lee CW, Yu J, Cho CH (2010) Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett 295:7–16PubMedCrossRef

36.

Greenhough A, Smartt HJM, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A (2009) The COX-2/PGE₂ pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377–386PubMedCrossRef

37.

Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E₂ promotes colon cancer cell growth through a G_s-axin-beta-catenin signaling axis. Science 310:1504–1510PubMedCrossRef

38.

Sheng HM, Shao JY, Washington MK, DuBois RN (2001) Prostaglandin E₂ increases growth and motility of colorectal carcinoma cells. J Biol Chem 276:18075–18081PubMedCrossRef

39.

Fukuda R, Kelly B, Semenza GL (2003) Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E₂ is mediated by hypoxia-inducible factor 1. Cancer Res 63:2330–2334PubMed

40.

Sakai H, Suzuki T, Takahashi Y, Ukai M, Tauchi K, Fujii T, Horikawa N, Minamimura T, Tabuchi Y, Morii M, Tsukada K, Takeguchi N (2006) Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A₂. FEBS Lett 580:3368–3374PubMedCrossRef

41.

Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ (1999) Thromboxane A₂ is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59:4574–4577PubMed

42.

Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K, Nukiwa T (2002) Gene transfer of thromboxane A₂ synthase and prostaglandin I₂ synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62:63–66PubMed

43.

Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Lonnroth C, Lundholm K (2007) Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol 46:1107–1112PubMedCrossRef

44.

Cutler NS, Graves-Deal R, LaFleur BJ, Gao ZQ, Boman BM, Whitehead RH, Terry E, Morrow JD, Coffey RJ (2003) Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res 63:1748–1751PubMed

45.

Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T, Wakabayashi K (2002) Involvement of prostaglandin E receptor subtype EP₄ in colon carcinogenesis. Cancer Res 62:28–32PubMed

46.

Qualtrough D, Kaidi A, Chell S, Jabbour HN, Williams AC, Paraskeva C (2007) Prostaglandin F_2α stimulates motility and invasion in colorectal tumor cells. Int J Cancer 121:734–740PubMedCrossRef

47.

Goldblatt D, Thrasher AJ (2000) Chronic granulomatous disease. Clin Exp Immunol 122:1–9PubMedCrossRef

48.

Morimoto K, Janssen WJ, Terada M (2012) Defective efferocytosis by alveolar macrophages in IPF patients. Respir Med 106:1800–1803PubMedCrossRef

49.

Imanishi T, Akasaka T (2013) Novel strategies to target inflammatory processes in atherosclerosis. Curr Pharm Des (in press)

50.

Herlong JL, Scott TR (2006) Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett 102:121–131PubMedCrossRef

51.

Ragolia L, Palaia T, Hall CE, Klein J, Buyud A (2010) Diminished lipocalin-type prostaglandin D₂ synthase expression in human lung tumors. Lung Cancer 70:103–109PubMedCrossRef

52.

Payne CA, Maleki S, Messina M, O’Sullivan MG, Stone G, Hall NR, Parkinson JF, Wheeler HR, Cook RJ, Biggs MT, Little NS, Teo C, Robinson BG, McDonald KL (2008) Loss of prostaglandin D₂ synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma. Mol Cancer Ther 7:3420–3428PubMedCrossRef

53.

Eichele K, Ramer R, Hinz B (2008) Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutics-induced apoptosis of human cervical carcinoma cells. Oncogene 27:3032–3044PubMedCrossRef

54.

Murata T, Aritake K, Matsumoto S, Kamauchi S, Nakagawa T, Hori M, Momotani E, Urade Y, Ozaki H (2011) Prostagladin D₂ is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci U S A 108:19802–19807PubMedCrossRef

55.

Park JM, Kanaoka Y, Eguchi N, Aritake K, Grujic S, Materi AM, Buslon VS, Tippin BL, Kwong AM, Salido E, French SW, Urade Y, Lin HJ (2007) Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in Apc^Min/+ mice. Cancer Res 67:881–889PubMedCrossRef

56.

Janakiram NB, Rao CV (2009) Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Curr Mol Med 9:565–579PubMedCrossRef

57.

Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussali MJ, Spindler SA, Greenson JK, Normolle D, Hasan AA, Lawrence TS, Brenner DE (1999) Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis 20:1985–1995

58.

Kamitani H, Geller M, Eling T (1998) Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J Biol Chem 273:21569–21577PubMedCrossRef

59.

Kim JS, Baek SJ, Bottone FG, Sali T, Eling TE (2005) Overexpression of 15-lipoxygenase-1 induces growth arrest through phosphorylation of p53 in human colorectal cancer cells. Mol Cancer Res 3:511–517PubMedCrossRef

60.

Yuri M, Sasahira T, Nakai K, Ishimaru S, Ohmori H, Kuniyasu H (2007) Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer. Histopathology 51:520–527PubMedCrossRef

61.

Jiang WG, Douglas-Jones A, Mansel RE (2003) Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent 69:275–281CrossRef

62.

Kure I, Nishiumi S, Nishitani Y, Tanoue T, Ishida T, Mizuno M, Fujita T, Kutsumi H, Arita M, Azuma T, Yoshida M (2010) Lipoxin A₄ reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappaB activation. J Pharmacol Exp Ther 332:541–548PubMedCrossRef

63.

Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG (2002) Lipoxin A₄ and aspirin-triggered 15-epi-lipoxin A₄ inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A 99:13266–13271PubMedCrossRef

64.

Hachicha M, Pouliot M, Petasis NA, Serhan CN (1999) Lipoxin (LX)A₄ and aspirin-triggered 15-epi-LXA₄ inhibit tumor necrosis factor 1 alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med 189:1923–1929PubMedCrossRef

65.

Hao H, Liu M, Wu P, Cai L, Tang K, Yi P, Li YS, Chen Y, Ye DY (2011) Lipoxin A₄ and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Lett 309:85–94PubMedCrossRef

66.

Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A, Mizuno S, Takagawa T, Morita Y, Kutsumi H, Inokuchi H, Serhan CN, Blumberg RS, Azuma T (2010) Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm Bowel Dis 16:87–95PubMedCrossRef

67.

Nowak J, Weylandt KH, Habbel P, Wang J, Dignass A, Glickman JN, Kang JX (2007) Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis 28:1991–1995PubMedCrossRef

68.

Harris SG, Smith RS, Phipps RP (2002) 15-Deoxy-Δ^12,14-PGJ₂ induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway. J Immunol 168:1372–1379PubMed

69.

Okano H, Shiraki K, Inoue H, Yamanaka Y, Kawakita T, Saitou Y, Yamaguchi Y, Enokimura N, Yamamoto N, Sugimoto K, Murata K, Nakano T (2003) 15-Deoxy-Δ^12,14-PGJ₂ regulates apoptosis induction and nuclear factor-kappa B activation via a peroxisome proliferator-activated receptor-gamma-independent mechanism in hepatocellular carcinoma. Lab Invest 83:1529–1539PubMedCrossRef

Titel: Resolution of inflammation as a novel chemopreventive strategy
verfasst von: Ha-Na Lee
Hye-Kyung Na
Young-Joon Surh
Publikationsdatum: 01.03.2013
Verlag: Springer-Verlag
Erschienen in: Seminars in Immunopathology / Ausgabe 2/2013
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-013-0363-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Introduction for inflammation and cancer

The role of PGE2-associated inflammatory responses in gastric cancer development

Protumor and antitumor functions of neutrophil granulocytes

Mast cells and inflammation-associated colorectal carcinogenesis

Helicobacter pylori infection and gastric carcinogenesis in rodent models